Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.
Rare Cancer Series | HPV-Negative Cervical Cancer
Dr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.
The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.
Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5